CAMBRIDGE, UK (2018-06-25) ProteinLogic (PL), the biomarker discovery and exploitation company, was invited to present its latest findings at the 8th McGill University’s Summer Institute for Advanced TB Diagnostics, held on the 18th-22nd of June 2018, in Montreal, Canada. CEO Nicolas Huber presented PL’s exciting developments in TB diagnosis to participants from the global TB…
News and Press
ProteinLogic Joins BIVDA
CAMBRIDGE, UK (2018-06-06) – ProteinLogic the biomarker discovery and exploitation company has become an affiliate member of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national trade association for companies with major involvement and interest in the In Vitro Diagnostics (IVD) industry and has represented manufacturers and distributors of IVD products for over…
ProteinLogic Presents At Bio€quity 2018, Ghent, Belgium
CAMBRIDGE, UK (2018-05-17) – ProteinLogic attended 19th Bio€quity Europe event, held in Ghent, Belgium. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies. ProteinLogic was invited to present to a panel of investors and…
ProteinLogic At BioTrinity 2018, London, UK
CAMBRIDGE, UK (2018-04-26) – ProteinLogic attended BioTrinity 2018, Europe’s leading biopartnering and investment conference. During the event, ProteinLogic delegates took advantage of the partnering environment to provide exposure of our technology, and our validated TB diagnostic to investors and life-sciences key players. The event included panel discussions of significant interest, especially regarding market access globally, the…
ProteinLogic Appoints Darleen Welford as VP of Regulatory Affairs and Quality Assurance
CAMBRIDGE UK (2018- 03- 05) – ProteinLogic, the biomarker discovery and exploitation company has appointed Darleen Welford as VP of Regulatory Affairs and Quality Assurance (RA/QA) to bring valuable global regulatory expertise, and to further the company’s RA strategy. Darleen has over 19 years’ experience in the field of In Vitro Diagnostic Medical Devices and…
ProteinLogic Appoints Dr Nicolas Huber as Chief Executive Officer
CAMBRIDGE, UK (2018-02-19) – ProteinLogic, the biomarker discovery company, has appointed Dr Nicolas Huber as its Chief Executive Officer. Dr Huber holds a Masters degree in electronic engineering and a PhD in Space Science from the University of Sussex. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past…
48th Union World Conference on Lung Health in Guadalajara, Mexico
ProteinLogic attended the 48th Union World Conference on Lung Health held in Guadalajara, Mexico, held on 11th-14th October 2017. The conference theme was ‘Accelerating Toward Elimination’. There was a focus on how to accelerate toward elimination of Tuberculosis. Numerous prominent scientists and global thought leaders emphasised the need for pro-active steps to find people with…
ProteinLogic develops a Rule-Out Test for Active TB
CAMBRIDGE, UK (2017-08-30) – ProteinLogic, a biomarker discovery company, funded by a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB), has achieved a significant milestone. In 2015, 10.4 million people fell ill with TB and 1.8 million died from the disease….
ProteinLogic appoints Dr Alex Betz as Chief Scientific Officer
CAMBRIDGE, UK (2016-05-03) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Alex Betz as Chief Scientific Officer to manage the scientific, research, technological and developmental operations. As a long standing non-executive director of the Company, Alex has helped set the company research and scientific priorities so that they line up with the…
ProteinLogic appoints Dr Roslin Russell as VP Bioinformatics & Computational Biology
ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Roslin Russell as Vice President of Bioinformatics & Computational Biology to bring technical expertise in the execution of the company’s R&D strategy. Before joining ProteinLogic, Roslin Russell spent eight years working for the Cambridge Institute, Cancer Research UK, as a computational biologist specialising in high-throughput…